TRANSCELERATE BIOPHARMA INC: Form 990, tax year 2021
View the entire original 990 at ProPublica ↗
- Organization
- TRANSCELERATE BIOPHARMA INC (EIN 46-0886344)
- Tax period
- 2021-01-01 to 2021-12-31
- Filed
- 2022-05-13
- IRS object ID
- 202221339349303127
- Schema version
- 2021v4.2
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2022-05-13T10:02:44-05:00 | ReturnTs |
| Tax Period End | 2021-12-31 | TaxPeriodEndDt |
Preparer Firm PreparerFirmGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Firm EIN | 871353108 | PreparerFirmEIN |
Preparer Firm Name PreparerFirmName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | EISNER ADVISORY GROUP LLC | BusinessNameLine1Txt |
Preparer US Address PreparerUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 130 NORTH 18TH STREET SUITE 3000 | AddressLine1Txt |
| City | PHILADELPHIA | CityNm |
| State Abbreviation | PA | StateAbbreviationCd |
| ZIP | 191032757 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2021-01-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 460886344 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | TRANSCELERATE BIOPHARMA INC | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Control | TRAN | BusinessNameControlTxt |
| Phone | 4845391230 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 300 CONSHOHOCKEN STATE ROAD 420 | AddressLine1Txt |
| City | WEST CONSHOHOCKEN | CityNm |
| State Abbreviation | PA | StateAbbreviationCd |
| ZIP | 19428 | ZIPCd |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | DALVIR GILL PHD | PersonNm |
| Person Title | CEO | PersonTitleTxt |
| Phone | 4845391230 | PhoneNum |
| Signature | 2022-05-04 | SignatureDt |
| Discuss With Paid Preparer | Yes (1) | DiscussWithPaidPreparerInd |
Signing Officer SigningOfficerGrp
Person Full Name PersonFullName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person First | DALVIR | PersonFirstNm |
| Person Last | GILL PHD | PersonLastNm |
| Field | Value | IRS element (for citing) |
|---|---|---|
| SSN | 999009999 | SSN |
Preparer Person PreparerPersonGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Person | HELEN M MARTIN | PreparerPersonNm |
| PTIN | P01330899 | PTIN |
| Phone | 2158818800 | PhoneNum |
Additional Filer Information AdditionalFilerInformation
Trusted Customer TrustedCustomerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Trusted Customer | 3 | TrustedCustomerCd |
| Authentication Assurance Level | AAL1 | AuthenticationAssuranceLevelCd |
| Identity Assurance Level | IAL1 | IdentityAssuranceLevelCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2021 | TaxYr |
| Build TS | 2022-09-23 18:48:47Z | BuildTS |
Form 990 IRS990
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Change | Yes (X) | AddressChangeInd |
| Principal Officer | DALVIR GILL PHD | PrincipalOfficerNm |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 300 CONSHOHOCKEN STATE ROAD 420 | AddressLine1Txt |
| City | WEST CONSHOHOCKEN | CityNm |
| State Abbreviation | PA | StateAbbreviationCd |
| ZIP | 19428 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $31,090,660 | GrossReceiptsAmt |
| Group Return For Affiliates | 0 | GroupReturnForAffiliatesInd |
| Organization501c | Yes (X) | Organization501cInd |
| Website Address | WWW.TRANSCELERATEBIOPHARMAINC.COM | WebsiteAddressTxt |
| Type Of Organization Corp | Yes (X) | TypeOfOrganizationCorpInd |
| Formation | 2012 | FormationYr |
| Legal Domicile State | DE | LegalDomicileStateCd |
| Activity Or Mission | IMPROVE THE HEALTH OF PEOPLE IN THE WORLD BY ENHANCING THE R&D OF INNOVATIVE THERAPIES.TRANSCELERATE BIOPHARMA INC. IS A NON-PROFIT ORGANIZATION DEDICATED TO IMPROVING THE HEALTH OF PEOPLE AROUND THE WORLD BY ACCELERATING AND ENHANCING THE RESEARCH AND DEVELOPMENT (R&D) OF INNOVATIVE NEW THERAPIES. THE ORGANIZATION'S MISSION IS TO COLLABORATE ACROSS THE GLOBAL BIOPHARMACEUTICAL R&D COMMUNITY TO IDENTIFY, DESIGN AND FACILITATE IMPLEMENTATION OF SOLUTIONS DESIGNED TO DRIVE THE EFFICIENT, EFFECTIVE AND HIGH QUALITY DELIVERY OF NEW MEDICINES.MEMBERSHIP IN TRANSCELERATE IS OPEN TO BIOPHARMACEUTICAL COMPANIES WITH RESEARCH & DEVELOPMENT OPERATIONS. | ActivityOrMissionDesc |
| Voting Members Governing Body | 20 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 19 | VotingMembersIndependentCnt |
| Total Employee | 26 | TotalEmployeeCnt |
| Total Volunteers | 0 | TotalVolunteersCnt |
| Total Gross UBI | $0 | TotalGrossUBIAmt |
| Net Unrelated Bus Txbl Incm | $0 | NetUnrelatedBusTxblIncmAmt |
| PY Contributions Grants | $0 | PYContributionsGrantsAmt |
| CY Contributions Grants | $0 | CYContributionsGrantsAmt |
| PY Program Service Revenue | $31,908,666 | PYProgramServiceRevenueAmt |
| CY Program Service Revenue | $31,089,166 | CYProgramServiceRevenueAmt |
| PY Investment Income | $66,228 | PYInvestmentIncomeAmt |
| CY Investment Income | $1,494 | CYInvestmentIncomeAmt |
| PY Other Revenue | $0 | PYOtherRevenueAmt |
| CY Other Revenue | $0 | CYOtherRevenueAmt |
| PY Total Revenue | $31,974,894 | PYTotalRevenueAmt |
| CY Total Revenue | $31,090,660 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $0 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $0 | CYGrantsAndSimilarPaidAmt |
| PY Benefits Paid To Members | $0 | PYBenefitsPaidToMembersAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $7,623,942 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $7,917,435 | CYSalariesCompEmpBnftPaidAmt |
| PY Total Prof Fndrsng Expns | $0 | PYTotalProfFndrsngExpnsAmt |
| CY Total Prof Fndrsng Expns | $0 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $0 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $20,484,023 | PYOtherExpensesAmt |
| CY Other Expenses | $25,262,906 | CYOtherExpensesAmt |
| PY Total Expenses | $28,107,965 | PYTotalExpensesAmt |
| CY Total Expenses | $33,180,341 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | $3,866,929 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | -$2,089,681 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $49,374,410 | TotalAssetsBOYAmt |
| Total Assets EOY | $50,373,384 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $36,650,129 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $39,738,784 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | $12,724,281 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | $10,634,600 | NetAssetsOrFundBalancesEOYAmt |
| Info In Schedule O Part III | Yes (X) | InfoInScheduleOPartIIIInd |
| Mission | TRANSCELERATE BIOPHARMA INC. IS DEDICATED TO IMPROVING THE HEALTH OF PEOPLE AROUND THE WORLD BY ACCELERATING AND ENHANCING THE RESEARCH AND DEVELOPMENT (R&D) OF INNOVATIVE NEW THERAPIES.THE ORGANIZATION'S MISSION IS TO COLLABORATE ACROSS THE GLOBAL BIOPHARMACEUTICAL R&D COMMUNITY TO IDENTIFY, DESIGN AND FACILITATE IMPLEMENTATION OF SOLUTIONS DESIGNED TO DRIVE THE EFFICIENT, EFFECTIVE AND HIGH QUALITY DELIVERY OF NEW MEDICINES. TRANSCELERATE EVOLVED FROM CONVERSATIONS AT VARIOUS FORUMS FOR EXECUTIVE R&D LEADERSHIP TO DISCUSS CURRENT ISSUES FACING THE INDUSTRY, AND EXAMINE SOLUTIONS FOR ADDRESSING COMMON CHALLENGES.MEMBERSHIP IN TRANSCELERATE IS OPEN TO BIOPHARMACEUTICAL COMPANIES WITH RESEARCH & DEVELOPMENT OPERATIONS. | MissionDesc |
| Significant New Program Srvc | 0 | SignificantNewProgramSrvcInd |
| Significant Change | 0 | SignificantChangeInd |
| Expense | $24,885,823 | ExpenseAmt |
| Revenue | $31,089,166 | RevenueAmt |
| Desc | OUTLINED BELOW ARE A FEW OF THE NUMEROUS YEAR-END ACHIEVEMENTS THROUGHOUT THE TRANSCELERATE PORTFOLIO.THE DIGITAL DATA FLOW INITIATIVE COMMENCED DEVELOPMENT ON A REFERENCE IMPLEMENTATION OF A STUDY DEFINITIONS REPOSITORY. THE STUDY DEFINITIONS REPOSITORY IS A NOVEL CENTRAL COMPONENT AIMED AT FACILITATING THE EXCHANGE OF STRUCTURED STUDY DEFINITIONS ACROSS CLINICAL SYSTEMS USING TECHNICAL AND DATA STANDARDS.THE STRATEGIC PRIORITY, IMPROVE THE PATIENT EXPERIENCE, LAUNCHED THE DIVERSITY OF PARTICIPANTS IN CLINICAL TRIALS INITIATIVE TO HELP EQUIP SPONSORS AND ECOSYSTEM STAKEHOLDERS WITH THE ACTIONABLE TOOLS AND RESOURCES NEEDED TO IMPROVE OUTCOMES FOR DIVERSIFICATION OF PARTICIPANTS IN CLINICAL TRIALS. AS PART OF THE FIRST PHASE OF THE INITIATIVE, THE FOLLOWING EFFORTS ARE UNDERWAY: DEVELOPING A CLINICAL RESEARCH DIVERSITY COLLABORATION HUB, RACE AND ETHNICITY ENROLLMENT DATA BENCHMARKING, AND BEST PRACTICES FOR SPONSORS AND CLINICAL TRIAL SITES. THIS INITIATIVE HOSTED TWO DIVERSITY ROUNDTABLE EVENTS. TRANSCELERATE'S MODERNIZING CLINICAL TRIAL CONDUCT (MCTC) INITIATIVE, IN COLLABORATION WITH THE RISK BASED MONITORING (RBM) INITIATIVE, RELEASED A PUBLICLY-AVAILABLE REPORT SHARING VOLUNTARY SURVEY DATA RELATED TO RBM ACTIVITIES PRE-COVID-19: "RESULTS OF RBM SDV/ SDR SURVEY: 2020 PRE-COVID-19 PANDEMIC PRACTICES." THIS REPORT SERVES AS THE FINAL DELIVERABLE OF THE RECENTLY COMPLETED RBM INITIATIVE. THIS INITIATIVE ALSO RELEASED AN OPERATIONAL COMPLEXITY ASSESSMENT TOOL WHICH IS AN INTERACTIVE TOOL THAT ASSESSES THE COMPLEXITY OR LACK OF COMPLEXITY OF IMPLEMENTING SELECTED MODERN SOLUTIONS IN A CLINICAL TRIAL.THE PATIENT EXPERIENCE INITIATIVE UPDATED TWO KEY SOLUTIONS, THE PATIENT PROTOCOL ENGAGEMENT TOOLKIT (P-PET) USER GUIDE AND THE P-PET RESOURCE GUIDE, TO INCLUDE NEW CONSIDERATIONS RELATED TO CAREGIVERS IN CLINICAL TRIALS AS WELL AS BEST PRACTICES FOR ENGAGING PATIENTS AND CAREGIVERS IN A VIRTUAL ENVIRONMENT. THE INITIATIVE ALSO RELEASED JAPANESE TRANSLATIONS OF THE P-PET, USER GUIDE VERSION 1.5, AND RESOURCE GUIDE VERSION 1.5, AND MORE THAN 15 DIFFERENT TRANSLATIONS OF THE STUDY PARTICIPANT FEEDBACK QUESTIONNAIRE (SPFQ).THE PATIENT TECHNOLOGY INITIATIVE UPDATED ITS PATIENTS CONSIDERATIONS GUIDE AND PATIENT TECHNOLOGY SITE FEEDBACK QUESTIONNAIRE (PTSFQ) TO INCLUDE CONSIDERATIONS AROUND DECENTRALIZED TRIALS AND VIRTUAL ENVIRONMENTS AND PUBLISHED ITS NOVEL DIGITAL ENDPOINTS PAPER "DEVELOPING A NOVEL MEASUREMENT OF SLEEP IN RHEUMATOID ARTHRITIS: STUDY PROPOSAL FOR APPROACH AND CONSIDERATIONS."TRANSCELERATE'S STRATEGIC PRIORITY, IMPROVE THE SITE EXPERIENCE, UPDATED AND RELEASED A NEW GOOD CLINICAL PRACTICE (GCP) MUTUAL RECOGNITION WEBSITE TO IMPROVE USER EXPERIENCE AS PART OF THE SITE QUALIFICATION & TRAINING (SQT) INITIATIVE. AS PART OF THIS UPGRADE, THERE IS NOW INTEGRATION WITH THE SHARED INVESTIGATOR PLATFORM (SIP). SQT ALSO CREATED AN INFORMATIONAL VIDEO ON ITS GCP MUTUAL RECOGNITION PROGRAM.THE MODERNIZATION OF STATISTICAL ANALYTICS INITIATIVE LAUNCHED ITS FOUNDATIONAL FRAMEWORK TO EXPLORE A PRODUCT-AGNOSTIC APPROACH TO BUILD TRUSTWORTHINESS OF USING MODERN STATISTICAL SOFTWARE TOOLS FOR REGULATORY DECISION-MAKING. THE FRAMEWORK INCLUDES PRINCIPLES THAT CAN BE USED BY REGULATORS AND OTHERS ACROSS THE INDUSTRY TO ESTABLISH A HIGH LEVEL OF ACCURACY, TRACEABILITY, AND REPRODUCIBILITY WITH REGARD TO REGULATORY SUBMISSIONS. ACCOMPANYING THIS FRAMEWORK IS AN INFOGRAPHIC AND CASE FOR ADOPTION.THE PROTOCOL DEVIATIONS INITIATIVE PUBLISHED A MANUSCRIPT ENTITLED, "PROTOCOL DEVIATIONS: A HOLISTIC APPROACH FROM DEFINING TO REPORTING." IN ADDITION TO THE PAPER, THE TEAM MADE UPDATES TO ITS PROTOCOL DEVIATION DECISION TREE AND PROTOCOL DEVIATION PROCESS GUIDE.THE DATA MONITORING COMMITTEE (DMC) INITIATIVE SUCCESSFULLY TRANSITIONED ITS EXISTING MATERIALS TO THE SOCIETY FOR CLINICAL TRIALS (SCT). USING TRANSCELERATE-DEVELOPED SOLUTIONS INCLUDING A DMC REGISTRY PROTOTYPE EBOOK, PROOF OF CONCEPT VIDEO, AND DMC APPRENTICESHIP MODEL OVERVIEW, SCT LAUNCHED ITS OWN DMC INITIATIVE BRINGING THE CONCEPT TO LIFE. THE SCT DMC INITIATIVE OFFERS ITS MEMBERS TRAINING, A REGISTRY FOR INDIVIDUALS WHO ARE INTERESTED IN SERVING AS DMC MEMBERS, AND MENTORING OPPORTUNITIES. THIS INITIATIVE IS NOW COMPLETE WITH NO NEW DELIVERABLES OR UPDATES PLANNED.THE INTERPRETATION OF CLINICAL GUIDANCES AND REGULATIONS INITIATIVE PUBLISHED ITS FRAMEWORK PAPER, "HISTORICAL BENCHMARKS FOR QUALITY TOLERANCE LIMITS PARAMETERS IN CLINICAL TRIALS."THE CLINICAL CONTENT & REUSE (CC&R) INITIATIVE RELEASED JAPANESE TRANSLATIONS OF THE COMMON PROTOCOL TEMPLATE (CPT) AND PATIENT LIBRARY. CC&R ALSO RELEASED ITS 2021 UPDATE, WHICH INCLUDES CLINICAL TEMPLATE SUITE ENHANCEMENTS FOR REGISTRY AUTOMATION AND MODEL CONTENT QUALITY, INCORPORATION OF PANDEMIC-RELATED LEARNING, ESTIMAND CLARIFICATIONS, AND ETEMPLATES TECHNICAL FRAMEWORK UPDATES, AMONG OTHER ITEMS.THE ESOURCE INITIATIVE RELEASED THE ESOURCE INFORMATICS CONTINUUM AND REFERENCE GUIDE FOR CLINICAL RESEARCH SITES, WHICH PROVIDES INFORMATION ON CLINICAL RESEARCH INFORMATICS, THE BASICS OF INFORMATICS, AND POSSIBLE RESOURCES TO EXPAND CAPABILITIES AROUND INTEROPERABILITY AND DATA EXCHANGE FOR CLINICAL SITES. IT IS ACCOMPANIED BY THE ESOURCE INFORMATICS CONTINUUM. THIS INITIATIVE CONTINUED PARTICIPATION AND LEADERSHIP IN VULCAN, AN HL7 FHIR ACCELERATOR. DATACELERATE UNDERWENT INFRASTRUCTURE ENHANCEMENTS ACROSS THE PLATFORM TO BETTER FACILITATE DATA SHARING.THE HISTORICAL TRIAL DATA SHARING INITIATIVE DEVELOPED AN ADOPTION FRAMEWORK: 5 ENABLERS OF DATA SHARING. THIS FRAMEWORK DETAILS THE KEY PRINCIPLES THAT CAN HELP PARTICIPANTS IN TRANSCELERATE DEVELOP DATA SHARING PROCESSES AND PROCEDURES.THE PRIVACY METHODOLOGY FOR DATA SHARING INITIATIVE DEVELOPED ITS FIRST-EVER OVERVIEW OF ITS BENEFITS AND GOALS.TRANSCELERATE'S INTELLIGENT AUTOMATION OPPORTUNITIES (IAO) IN PHARMACOVIGILANCE INITIATIVE PUBLISHED THE PAPER "VALIDATING INTELLIGENT AUTOMATION SYSTEMS IN PHARMACOVIGILANCE: INSIGHTS FROM GOOD MANUFACTURING PRACTICES." THE IAO INITIATIVE ALSO HELD KEY HEALTH AUTHORITIES MEETINGS WITH THE FDA, EMA, AND HEALTH CANADA TO DISCUSS ITS PROGRESS AND VALIDATION PROPOSAL. IN ADDITION, THE TEAM CONTINUED ITS COLLABORATION WITH MHRA DURING TWO SESSIONS AT DIA EUROPE. THE INTERPRETATION OF PHARMACOVIGILANCE GUIDANCES & REGULATIONS INITIATIVE COMMENCED WORK ON ITS NEWEST TOPIC CONCERNING THE MULTIPLE NEW REGULATORY GUIDELINES GOVERNING THE USE OF MEDICINES IN PREGNANCY AND BREASTFEEDING. THE PHARMACOVIGILANCE AGREEMENTS OPTIMIZATION (PVAO) INITIATIVE TEAM LAUNCHED ITS SOLUTIONS PAGE, AN INTERACTIVE PROCESS MAP, AND A GLOSSARY. THE VALUE OF SAFETY INFORMATION DATA SOURCES (VSIDS) INITIATIVE RELEASED THE INFOGRAPHIC "IDENTIFYING THE VALUE OF INFORMATION DATA SOURCES TO IMPROVE PATIENT SAFETY."BIOCELERATE'S COMMON TEMPLATES FOR NONCLINICAL STUDIES PRESENTED THE POSTER "SUPPORTING EFFICIENCIES IN NONCLINICAL TOXICOLOGY STUDIES THROUGH COMMON TEMPLATES" AT THE SOCIETY OF TOXICOLOGY ANNUAL MEETING AND PRESENTED THE POSTER "SUPPORTING EFFICIENCIES IN NONCLINICAL TOXICOLOGY STUDIES THROUGH PROTOCOL AND REPORT TEMPLATES: PROGRESS TOWARDS ADOPTION" AT THE AMERICAN COLLEGE OF TOXICOLOGY ANNUAL MEETING. THIS INITIATIVE ALSO COMPLETED ITS INTERNAL PHASE 1 PILOT WITH VOLUNTARY PARTICIPATION FROM ALL BIOCELERATE COMPANIES TO ASSESS THE VALUE AND FUNCTION OF ITS TEMPLATES COMPARED TO TEMPLATES USED BY PARTICIPATING COMPANIES.THE SEND HARMONIZATION FOR CROSS-STUDY ANALYSIS INITIATIVE EXTENDED ITS PUBLIC PRIVATE PARTNERSHIP (PPP) WITH THE U.S. FDA'S CENTER FOR DRUG EVALUATION AND RESEARCH OFFICE OF COMPUTATIONAL SCIENCE TO CONTINUE TO CREATE RESOURCES AND TOOLS TO AID SEND IMPLEMENTATION FOR CROSS-STUDY ANALYSIS AND PUBLISHED ITS MANUSCRIPT "LEVERAGING THE VALUE OF CDISC SEND DATASETS FOR CROSS-STUDY ANALYSIS: INCIDENCE OF MICROSCOPIC FINDINGS IN CONTROL ANIMALS." AS PART OF A COLLABORATION WITH PHUSE, A WHITE PAPER "RECOMMENDATIONS FOR POPULATING CONTROL TYPE (TCNTRL) WITH CDISC SEND CONTROLLED TERMINOLOGY" WAS PUBLISHED. THE SEND INITIATIVE ALSO HOSTED THE "COLLABORATIVELY CRACKING THE SEND CODE: UNLOCKING THE POTENTIAL VALUE OF STANDARDIZED TOXICOLOGY STUDY DATA" WORKSHOP AT THE AMERICAN COLLEGE OF TOXICOLOGY ANNUAL MEETING.TOXICOLOGY & BACKGROUND CONTROL DATA SHARING SIGNIFICANTLY INCREASED THE NUMBER OF SEND FORMAT TOXICOLOGY AND BACKGROUND AND CONTROL STUDIES IN THE TOXICOLOGY DATA SHARING DATABASE AND LAUNCHED THE DATACELERATE SEARCH ENHANCEMENT RELEASE FOR THE TOXICOLOGY AND BACKGROUND CONTROL MODULES TO SIGNIFICANTLY ENHANCE THE USABILITY AND SEARCHABILITY OF THE TDS DATABASE. | Desc |
| Total Program Service Expenses | $24,885,823 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | 0 | DescribedInSection501c3Ind |
| Schedule B Required | 0 | ScheduleBRequiredInd |
| Political Campaign Acty | 0 | PoliticalCampaignActyInd |
| Subject To Proxy Tax | Yes (1) | SubjectToProxyTaxInd |
| Donor Advised Fund | 0 | DonorAdvisedFundInd |
| Conservation Easements | 0 | ConservationEasementsInd |
| Collections Of Art | 0 | CollectionsOfArtInd |
| Credit Counseling | 0 | CreditCounselingInd |
| Donor Rstr Or Quasi Endowments | 0 | DonorRstrOrQuasiEndowmentsInd |
| Report Land Building Equipment | 0 | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | 0 | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | 0 | ReportProgramRelatedInvstInd |
| Report Other Assets | 0 | ReportOtherAssetsInd |
| Report Other Liabilities | 0 | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | 0 | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | 0 | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | 0 | ConsolidatedAuditFinclStmtInd |
| School Operating | 0 | SchoolOperatingInd |
| Foreign Office | 0 | ForeignOfficeInd |
| Foreign Activities | 0 | ForeignActivitiesInd |
| More Than5000 K To Org | 0 | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | 0 | MoreThan5000KToIndividualsInd |
| Professional Fundraising | 0 | ProfessionalFundraisingInd |
| Fundraising Activities | 0 | FundraisingActivitiesInd |
| Gaming Activities | 0 | GamingActivitiesInd |
| Operate Hospital | 0 | OperateHospitalInd |
| Grants To Organizations | 0 | GrantsToOrganizationsInd |
| Grants To Individuals | 0 | GrantsToIndividualsInd |
| Schedule J Required | Yes (1) | ScheduleJRequiredInd |
| Tax Exempt Bonds | 0 | TaxExemptBondsInd |
| Loan Outstanding | 0 | LoanOutstandingInd |
| Grant To Related Person | 0 | GrantToRelatedPersonInd |
| Business Rln With Org Mem | 0 | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | 0 | BusinessRlnWithFamMemInd |
| Business Rln With35 Ctrl Ent | 0 | BusinessRlnWith35CtrlEntInd |
| Deductible Non Cash Contri | 0 | DeductibleNonCashContriInd |
| Deductible Art Contribution | 0 | DeductibleArtContributionInd |
| Terminate Operations | 0 | TerminateOperationsInd |
| Partial Liquidation | 0 | PartialLiquidationInd |
| Disregarded Entity | Yes (1) | DisregardedEntityInd |
| Related Entity | 0 | RelatedEntityInd |
| Related Organization Ctrl Ent | 0 | RelatedOrganizationCtrlEntInd |
| Activities Conducted Prtshp | 0 | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (1) | ScheduleORequiredInd |
| IRP Document | 24 | IRPDocumentCnt |
| IRP Document W2 G | 0 | IRPDocumentW2GCnt |
| Backup Wthld Compliance | Yes (1) | BackupWthldComplianceInd |
| Employee | 26 | EmployeeCnt |
| Employment Tax Returns Filed | Yes (1) | EmploymentTaxReturnsFiledInd |
| Unrelated Bus Incm Over Limit | 0 | UnrelatedBusIncmOverLimitInd |
| Foreign Financial Account | 0 | ForeignFinancialAccountInd |
| Prohibited Tax Shelter Trans | 0 | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | 0 | TaxablePartyNotificationInd |
| Nondeductible Contributions | 0 | NondeductibleContributionsInd |
| Indoor Tanning Services | 0 | IndoorTanningServicesInd |
| Subj To Tax Rmnrtn Ex Prcht Pymt | Yes (1) | SubjToTaxRmnrtnExPrchtPymtInd |
| Subject To Excs Tax Net Invst Inc | 0 | SubjectToExcsTaxNetInvstIncInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 20 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 19 | IndependentVotingMemberCnt |
| Family Or Business Rln | 0 | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | 0 | DelegationOfMgmtDutiesInd |
| Change To Org Documents | 0 | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | 0 | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | Yes (1) | MembersOrStockholdersInd |
| Election Of Board Members | Yes (1) | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | 0 | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | Yes (1) | MinutesOfGoverningBodyInd |
| Minutes Of Committees | Yes (1) | MinutesOfCommitteesInd |
| Officer Mailing Address | 0 | OfficerMailingAddressInd |
| Local Chapters | 0 | LocalChaptersInd |
| Form990 Provided To Gvrn Body | Yes (1) | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (1) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | Yes (1) | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | Yes (1) | RegularMonitoringEnfrcInd |
| Whistleblower Policy | Yes (1) | WhistleblowerPolicyInd |
| Document Retention Policy | 0 | DocumentRetentionPolicyInd |
| Compensation Process CEO | Yes (1) | CompensationProcessCEOInd |
| Compensation Process Other | Yes (1) | CompensationProcessOtherInd |
| Investment In Joint Venture | 0 | InvestmentInJointVentureInd |
| Upon Request | Yes (X) | UponRequestInd |
Books In Care Of Detail BooksInCareOfDetail
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | ANTHONY GARGES HEAD OF FINANCE AND ADMINISTRATION | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Phone | 4845391235 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1001 CONSHOHOCKEN STATE ROAD STE | AddressLine1Txt |
| City | WEST CONSHOHOCKEN | CityNm |
| State Abbreviation | PA | StateAbbreviationCd |
| ZIP | 19428 | ZIPCd |
Form990 Part VII Section A Form990PartVIISectionAGrp (31 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt | OfficerOfficerInd | Highest Compensated EmployeeHighestCompensatedEmployeeInd |
|---|---|---|---|---|---|---|---|
| ROD MACKENZIE | |||||||
| CHAIR OF BOARD OF DIRECTORS | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| KATHRYN OWEN | |||||||
| VICE CHAIR OF BOARD OF DIRECTORS | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| ROY BAYNES | |||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| DIETMAR BERGER | |||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| CHRIS CORSICO | |||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| MARTIN HOLST LANGE | |||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| ROB LENZ | |||||||
| BOARD MEMBER (EFF 03/26/21) | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| IRIS LOEW-FRIEDRICH | |||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| CRISTIAN MASSACESI | |||||||
| BOARD MEMBER (EFF 09/23/21) | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| ROBERT METCALF | |||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| JOHN OIDTMAN | |||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| STUART POULTON | |||||||
| BOARD MEMBER (EFF 06/21/21) | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| STEFFEN ROELLINGER | |||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| MICHELLE ROHRER | |||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| PETER RONCO | |||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| MEHDI SHAHIDI | |||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| BADHRI SRINIVASAN | |||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| TAKUKO YAMADA-SAWADA | |||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| BERNHARDT G ZEIHER | |||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| NEIL GALLAGHER | |||||||
| BOARD MEMBER (THRU 06/21/21) | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| ELLIOTT LEVY | |||||||
| BOARD MEMBER (THRU 03/26/21) | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| ANN TAYLOR | |||||||
| BOARD MEMBER (THRU 09/23/21) | 0.50 | Yes (X) | $0 | $0 | $0 | ||
| DALVIR GILL | |||||||
| CHIEF EXECUTIVE OFFICER | 40.00 | Yes (X) | $1,929,245 | $0 | $80,918 | Yes (X) | |
| ROBERT BAKER | |||||||
| CORPORATE SECRETARY | 0.50 | $0 | $0 | $0 | Yes (X) | ||
| ANDREW LEE | |||||||
| TREASURER | 0.50 | $0 | $0 | $0 | Yes (X) | ||
| JANICE CHANG | |||||||
| CHIEF OPERATING OFFICER | 40.00 | $770,503 | $0 | $41,169 | Yes (X) | ||
| JENNIFER A BURGESS | |||||||
| VP GLOBAL ENGAGEMENT AND COMM. | 40.00 | $394,547 | $0 | $50,265 | Yes (X) | ||
| CARA L RINALDI | |||||||
| EXEC DIRECTOR OF PORTFOLIO MGMT | 40.00 | $332,279 | $0 | $55,432 | Yes (X) | ||
| JENEEN DONADEO | |||||||
| SENIOR DIRECTOR OF PORTFOLIO MGMT | 40.00 | $315,440 | $0 | $36,273 | Yes (X) | ||
| ANTHONY GARGES | |||||||
| HEAD OF FINANCE AND ADMINISTRATION | 40.00 | $280,583 | $0 | $46,240 | Yes (X) | ||
| PATRICE WRIGHT | |||||||
| HEALTH AUTHORITY ENGAGEMENT DIRECTOR | 40.00 | $259,757 | $0 | $28,363 | Yes (X) | ||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $4,282,354 | TotalReportableCompFromOrgAmt |
| Tot Reportable Comp Rltd Org | $0 | TotReportableCompRltdOrgAmt |
| Total Other Compensation | $338,660 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 20 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | 0 | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | Yes (1) | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | 0 | CompensationFromOtherSrcsInd |
Contractor Compensation ContractorCompensationGrp (5 entries)
| Address Line1ContractorAddress/ForeignAddress/AddressLine1Txt | CityContractorAddress/ForeignAddress/CityNm | CountryContractorAddress/ForeignAddress/CountryCd | ServicesServicesDesc | CompensationCompensationAmt | Address Line1ContractorAddress/USAddress/AddressLine1Txt | CityContractorAddress/USAddress/CityNm | State AbbreviationContractorAddress/USAddress/StateAbbreviationCd | ZIPContractorAddress/USAddress/ZIPCd |
|---|---|---|---|---|---|---|---|---|
| PA CONSULTING GROUP INC | ||||||||
| 10 BRESSENDEN PLACE | LONDON | UK | CONSULTING SERVICES | $7,281,210 | ||||
| ACCENTURE LLP | ||||||||
| CONSULTING & IT SERVICES | $6,161,651 | 161 N CLARK STREET | CHICAGO | IL | 60601 | |||
| KILPATRICK TOWNSEND | ||||||||
| LEGAL SERVICES | $2,584,122 | 601 14TH STREET NW SUITE 900 | WASHINGTON | DC | 20005 | |||
| ARTEMIS FACTOR LLC | ||||||||
| CONSULTING SERVICES | $1,377,476 | 314 CARLYLE ROAD | WEST CHESTER | PA | 19382 | |||
| FLUID EDGE | ||||||||
| CONSULTING SERVICES | $1,343,651 | 10 MYSTIC LANE | MALVERN | PA | 19355 | |||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct Rcvd Greater Than100 K | 20 | CntrctRcvdGreaterThan100KCnt |
Program Service Revenue ProgramServiceRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Desc | MEMBERSHIP DUES | Desc |
| Business | 541900 | BusinessCd |
| Total Revenue Column | $31,089,166 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $31,089,166 | RelatedOrExemptFuncIncomeAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Program Service Revenue | $31,089,166 | TotalProgramServiceRevenueAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $1,494 | TotalRevenueColumnAmt |
| Exclusion | $1,494 | ExclusionAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $31,090,660 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $31,089,166 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | $1,494 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Info In Schedule O Part IX | Yes (X) | InfoInScheduleOPartIXInd |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,821,835 | TotalAmt |
| Management And General | $2,821,835 | ManagementAndGeneralAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $4,068,180 | TotalAmt |
| Program Services | $2,260,192 | ProgramServicesAmt |
| Management And General | $1,807,988 | ManagementAndGeneralAmt |
Pension Plan Contributions PensionPlanContributionsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $166,868 | TotalAmt |
| Program Services | $66,699 | ProgramServicesAmt |
| Management And General | $100,169 | ManagementAndGeneralAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $521,749 | TotalAmt |
| Program Services | $203,718 | ProgramServicesAmt |
| Management And General | $318,031 | ManagementAndGeneralAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $338,803 | TotalAmt |
| Program Services | $137,693 | ProgramServicesAmt |
| Management And General | $201,110 | ManagementAndGeneralAmt |
Fees For Services Legal FeesForServicesLegalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,575,346 | TotalAmt |
| Program Services | $1,739,668 | ProgramServicesAmt |
| Management And General | $835,678 | ManagementAndGeneralAmt |
Fees For Services Accounting FeesForServicesAccountingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $94,654 | TotalAmt |
| Management And General | $94,654 | ManagementAndGeneralAmt |
Fees For Services Other FeesForServicesOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $13,597,574 | TotalAmt |
| Program Services | $12,878,856 | ProgramServicesAmt |
| Management And General | $718,718 | ManagementAndGeneralAmt |
Advertising AdvertisingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $16,451 | TotalAmt |
| Program Services | $8,764 | ProgramServicesAmt |
| Management And General | $7,687 | ManagementAndGeneralAmt |
Office Expenses OfficeExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $158,129 | TotalAmt |
| Program Services | $996 | ProgramServicesAmt |
| Management And General | $157,133 | ManagementAndGeneralAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $7,877,110 | TotalAmt |
| Program Services | $7,586,027 | ProgramServicesAmt |
| Management And General | $291,083 | ManagementAndGeneralAmt |
Occupancy OccupancyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $221,196 | TotalAmt |
| Management And General | $221,196 | ManagementAndGeneralAmt |
Travel TravelGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $21,646 | TotalAmt |
| Program Services | $231 | ProgramServicesAmt |
| Management And General | $21,415 | ManagementAndGeneralAmt |
Conferences Meetings ConferencesMeetingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $10,415 | TotalAmt |
| Program Services | $2,979 | ProgramServicesAmt |
| Management And General | $7,436 | ManagementAndGeneralAmt |
Insurance InsuranceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $234,177 | TotalAmt |
| Management And General | $234,177 | ManagementAndGeneralAmt |
Other Expenses OtherExpensesGrp (4 entries)
| DescDesc | TotalTotalAmt | Management And GeneralManagementAndGeneralAmt |
|---|---|---|
| RECRUITING | $257,058 | $257,058 |
| EXCESS COMPENSATION TAX | $195,141 | $195,141 |
| BOOKS, SUBSCRIPTIONS, R | $2,317 | $2,317 |
| DUES | $1,692 | $1,692 |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $33,180,341 | TotalAmt |
| Program Services | $24,885,823 | ProgramServicesAmt |
| Management And General | $8,294,518 | ManagementAndGeneralAmt |
| Fundraising | $0 | FundraisingAmt |
Cash Non Interest Bearing CashNonInterestBearingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $18,363,859 | BOYAmt |
| EOY | $17,656,028 | EOYAmt |
Savings And Temp Cash Invst SavingsAndTempCashInvstGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $1,588,161 | BOYAmt |
| EOY | $0 | EOYAmt |
Accounts Receivable AccountsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $29,239,481 | BOYAmt |
| EOY | $32,595,000 | EOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $171,062 | BOYAmt |
| EOY | $83,526 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Bldg Equip Cost Or Other Bss | $0 | LandBldgEquipCostOrOtherBssAmt |
| Land Bldg Equip Accum Deprec | $0 | LandBldgEquipAccumDeprecAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Other Assets Total OtherAssetsTotalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $11,847 | BOYAmt |
| EOY | $38,830 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $49,374,410 | BOYAmt |
| EOY | $50,373,384 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $5,560,963 | BOYAmt |
| EOY | $6,206,784 | EOYAmt |
Deferred Revenue DeferredRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $31,089,166 | BOYAmt |
| EOY | $33,532,000 | EOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $36,650,129 | BOYAmt |
| EOY | $39,738,784 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Follows FASB117 | Yes (X) | OrganizationFollowsFASB117Ind |
No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $12,724,281 | BOYAmt |
| EOY | $10,634,600 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $12,724,281 | BOYAmt |
| EOY | $10,634,600 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $49,374,410 | BOYAmt |
| EOY | $50,373,384 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Reconcilation Revenue Expnss | -$2,089,681 | ReconcilationRevenueExpnssAmt |
| Other Changes In Net Assets | $0 | OtherChangesInNetAssetsAmt |
| Method Of Accounting Accrual | Yes (X) | MethodOfAccountingAccrualInd |
| Accountant Compile Or Review | 0 | AccountantCompileOrReviewInd |
| FS Audited | 0 | FSAuditedInd |
| Federal Grant Audit Required | 0 | FederalGrantAuditRequiredInd |
Schedule C IRS990ScheduleC
| Field | Value | IRS element (for citing) |
|---|---|---|
| Substantially All Dues Nonded | 0 | SubstantiallyAllDuesNondedInd |
| Only In House Lobbying | Yes (1) | OnlyInHouseLobbyingInd |
| Agree Carryover Prior Year | 0 | AgreeCarryoverPriorYearInd |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| Board Or Committee Approval | Yes (X) | BoardOrCommitteeApprovalInd |
| Severance Payment | 0 | SeverancePaymentInd |
| Supplemental Nonqual Rtr Plan | 0 | SupplementalNonqualRtrPlanInd |
| Equity Based Comp Arrngm | 0 | EquityBasedCompArrngmInd |
Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (7 entries)
| TitleTitleTxt | Base Compensation Filing OrgBaseCompensationFilingOrgAmt | Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt | Bonus Filing OrganizationBonusFilingOrganizationAmount | Bonus Related OrganizationsBonusRelatedOrganizationsAmt | Other Compensation Filing OrgOtherCompensationFilingOrgAmt | Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt | Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt | Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt | Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt | Total Compensation Filing OrgTotalCompensationFilingOrgAmt | Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt | Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt | Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DALVIR GILL | ||||||||||||||
| CHIEF EXECUTIVE OFFICER | $663,941 | $0 | $1,265,304 | $0 | $0 | $0 | $11,600 | $0 | $69,318 | $0 | $2,010,163 | $0 | $0 | $0 |
| JANICE CHANG | ||||||||||||||
| CHIEF OPERATING OFFICER | $517,870 | $0 | $252,633 | $0 | $0 | $0 | $11,600 | $0 | $29,569 | $0 | $811,672 | $0 | $0 | $0 |
| JENNIFER A BURGESS | ||||||||||||||
| VP GLOBAL ENGAGEMENT AND COMM. | $303,191 | $0 | $91,356 | $0 | $0 | $0 | $11,600 | $0 | $38,665 | $0 | $444,812 | $0 | $0 | $0 |
| CARA L RINALDI | ||||||||||||||
| EXEC DIRECTOR OF PORTFOLIO MGMT | $246,815 | $0 | $85,464 | $0 | $0 | $0 | $6,723 | $0 | $48,709 | $0 | $387,711 | $0 | $0 | $0 |
| JENEEN DONADEO | ||||||||||||||
| SENIOR DIRECTOR OF PORTFOLIO MGMT | $243,055 | $0 | $72,385 | $0 | $0 | $0 | $11,153 | $0 | $25,120 | $0 | $351,713 | $0 | $0 | $0 |
| ANTHONY GARGES | ||||||||||||||
| HEAD OF FINANCE AND ADMINISTRATION | $216,029 | $0 | $64,554 | $0 | $0 | $0 | $10,030 | $0 | $36,210 | $0 | $326,823 | $0 | $0 | $0 |
| PATRICE WRIGHT | ||||||||||||||
| HEALTH AUTHORITY ENGAGEMENT DIRECTOR | $208,257 | $0 | $51,500 | $0 | $0 | $0 | $6,336 | $0 | $22,027 | $0 | $288,120 | $0 | $0 | $0 |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 3 | FormAndLineReferenceDesc |
| Explanation | THE BOARD CHAIR, WITH INPUT FROM OTHER DIRECTORS OR A SUBCOMMITTEE OF THE BOARD, ANNUALLY REVIEWS AND APPROVES THE CEO'S COMPENSATION PACKAGE. | ExplanationTxt |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (7 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| FORM 990, PART VI, SECTION A, LINE 6 | THE MEMBERS OF THE CORPORATION CONSIST OF SUCH FIRMS AND CORPORATIONS THAT ARE APPROVED FOR MEMBERSHIP FROM TIME TO TIME BY THE BOARD OF DIRECTORS OR ITS DESIGNEES IN ACCORDANCE WITH THE POLICIES AND PROCEDURES OF THE CORPORATION. THE CORPORATION HAS THE FOLLOWING CATEGORIES OF MEMBERS: A. TIER I MEMBERS - TO BE ELIGIBLE FOR TIER I MEMBERSHIP, A FIRM OR CORPORATION MUST BE A PHARMACEUTICAL OR BIOTECHNOLOGY COMPANY WITH AN ANNUAL BUDGET FOR RESEARCH AND DEVELOPMENT IN EXCESS OF $2.5 BILLION. ELIGIBILITY FOR TIER I MEMBERSHIP IS ESTABLISHED BASED UPON A COMPANY'S PUBLICALLY AVAILABLE RESEARCH AND DEVELOPMENT EXPENDITURES OVER THE THREE (3) YEAR PERIOD PRECEDING THE DATE THE COMPANY APPLIES TO JOIN THE CORPORATION. THE INITIAL TIER I MEMBERS ARE FURTHER DEFINED AS THE "CHARTER MEMBERS." B. TIER II MEMBERS - TO BE ELIGIBLE FOR TIER II MEMBERSHIP, A FIRM OR CORPORATION MUST BE A PHARMACEUTICAL OR BIOTECHNOLOGY COMPANY WITH AN ANNUAL BUDGET FOR RESEARCH AND DEVELOPMENT THAT IS LESS THAN $2.5 BILLION BUT MORE THAN $100 MILLION. ELIGIBILITY FOR TIER II MEMBERSHIP WILL BE ESTABLISHED BASED UPON A COMPANY'S PUBLICALLY AVAILABLE RESEARCH AND DEVELOPMENT EXPENDITURES OVER THE THREE (3) YEAR PERIOD PRECEDING THE DATE THE COMPANY APPLIES TO JOIN THE CORPORATION. C. ASSOCIATE MEMBERS - TO BE ELIGIBLE FOR ASSOCIATE MEMBERSHIP, A FIRM OR CORPORATION MUST BE A PHARMACEUTICAL OR BIOTECHNOLOGY COMPANY WITH AN ANNUAL BUDGET FOR RESEARCH AND DEVELOPMENT THAT IS LESS THAN $100 MILLION. |
| FORM 990, PART VI, SECTION A, LINE 7A | THE BOARD OF DIRECTORS SHALL BE COMPRISED OF UP TO TWENTY-TWO (22) DIRECTORS; PROVIDED THAT: (I) TEN (10) SEATS ARE FILLED BY DIRECTORS WHO ARE REPRESENTATIVES OF THE CHARTER MEMBERS; (II) UP TO FOUR (4) ADDITIONAL SEATS SHALL BE FILLED BY DIRECTORS WHO ARE REPRESENTATIVES OF THE TIER I MEMBERS WHO ARE NOT CHARTER MEMBERS; (III) UP TO SIX (6) SEATS SHALL BE FILLED BY DIRECTORS WHO ARE REPRESENTATIVES OF THE TIER II MEMBERS; (IV) ONE (1) SEAT SHALL BE FILLED BY A DIRECTOR WHO IS A REPRESENTATIVE OF THE ASSOCIATE MEMBERS; AND (V) ONE (1) SEAT SHALL BE FILLED BY THE CHIEF EXECUTIVE OFFICER OF THE CORPORATION. THE CORPORATION'S BYLAWS STATE THAT DIRECTORS SHALL BE ELECTED OR APPOINTED, AS APPLICABLE, ANNUALLY AT THE ANNUAL MEETING OF MEMBERS AND SHALL SERVE UNTIL THE FOLLOWING ANNUAL MEETING OF MEMBERS AND UNTIL THEIR SUCCESSORS ARE ELECTED OR APPOINTED, AS APPLICABLE, AND QUALIFIED. EACH CHARTER MEMBER SHALL HAVE THE RIGHT TO APPOINT A REPRESENTATIVE OF THE CHARTER MEMBER TO SERVE AS A CHARTER MEMBER DIRECTOR. TIER I AT-LARGE DIRECTORS SHALL BE ELECTED BY A PLURALITY VOTE OF THE TIER I MEMBERS, WHICH INCLUDE THE CHARTER MEMBERS. TIER II DIRECTORS SHALL BE ELECTED BY A PLURALITY VOTE OF THE TIER II MEMBERS. ANY ASSOCIATE MEMBER DIRECTOR SHALL BE ELECTED BY A PLURALITY VOTE OF THE ASSOCIATE MEMBERS. THE CEO DIRECTOR SHALL SERVE EX-OFFICIO, FOR SO LONG AS HE OR SHE SHALL HOLD THE OFFICE OF CHIEF EXECUTIVE OFFICER. TRANSCELERATE DOES NOT PRESENTLY HAVE ANY ASSOICATE MEMBERS THEREFORE, THE ASSOICATE MEMBER BOARD SEAT IS CURRENTLY VACANT. EACH TIER I MEMBER SHALL BE ENTITLED TO THREE (3) VOTES AT EVERY MEETING OF MEMBERS ON MATTERS WHICH TIER 1 MEMBERS ARE ENTITLED TO VOTE. EACH TIER II MEMBER SHALL BE ENTITLED TO ONE (1) VOTE AT EVERY MEETING OF MEMBERS ON MATTERS WHICH TIER II MEMBERS ARE ENTITLED TO VOTE. ASSOCIATE MEMBERS SHALL BE ENTITLED TO NOTICE OF AND TO ATTEND MEETINGS OF THE MEMBERS BUT SHALL NOT BE ENTITLED TO VOTE AT SUCH MEETINGS, PROVIDED HOWEVER, ASSOCIATE MEMBERS SHALL HAVE THE RIGHT TO CAST ONE (1) VOTE EACH WITH RESPECT TO THE ELECTION OF THE NOMINEE TO FILL THE ASSOCIATE MEMBER BOARD POSITION. NOTWITHSTANDING THE ABOVE, IN ORDER TO BE ELIGIBLE TO VOTE, A MEMBER MUST BE IN GOOD STANDING AND ITS DUES AND ASSESSMENTS PAID IN FULL. |
| FORM 990, PART VI, SECTION B, LINE 11B | THE FINANCE COMMITTEE AND MANAGEMENT REVIEW AND APPROVE THE FORM 990. THE FORM IS THEN DISTRIBUTED TO ALL MEMBERS OF THE BOARD FOR THEIR REVIEW BEFORE FILING WITH THE INTERNAL REVENUE SERVICE. |
| FORM 990, PART VI, SECTION B, LINE 12C | EACH DIRECTOR AND OFFICER OF THE CORPORATION IS REQUIRED TO ANNUALLY ACKNOWLEDGE THE CONFLICT OF INTEREST POLICY, AFFIRMING THAT SUCH PERSON HAS RECEIVED, READ AND UNDERSTANDS, AND AGREED TO COMPLY WITH THE CONFLICT OF INTEREST POLICY. |
| FORM 990, PART VI, SECTION B, LINE 15 | THE BOARD CHAIR, WITH INPUT FROM OTHER DIRECTORS OR A SUBCOMMITTEE OF THE BOARD, ANNUALLY REVIEWS AND APPROVES THE CEO'S COMPENSATION PACKAGE. THE CEO APPROVES THE COMPENSATION FOR THE CHIEF OPERATING OFFICER, AND ALL OTHER KEY EMPLOYEES. |
| FORM 990, PART VI, SECTION C, LINE 19 | THE ORGANIZATION'S GOVERNING DOCUMENTS, FINANCIAL STATEMENTS, AND CONFLICT OF INTEREST POLICY AND OTHER CORPORATE POLICIES ARE AVAILABLE UPON REQUEST. |
| FORM 990, PART IX, LINE 11G | PROJECT MANAGEMENT FEES: PROGRAM SERVICE EXPENSES 8,414,185. MANAGEMENT AND GENERAL EXPENSES 15,493. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 8,429,678. EXTERNAL CONTRACTOR SUPPORT: PROGRAM SERVICE EXPENSES 1,725,587. MANAGEMENT AND GENERAL EXPENSES 56,078. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 1,781,665. COMMUNICATIONS FEES: PROGRAM SERVICE EXPENSES 188,701. MANAGEMENT AND GENERAL EXPENSES 647,147. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 835,848. CHANGE MANAGEMENT FEES: PROGRAM SERVICE EXPENSES 2,550,383. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 2,550,383. |
Schedule R IRS990ScheduleR
Id Disregarded Entities IdDisregardedEntitiesGrp
Disregarded Entity Name DisregardedEntityName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | BIOCELERATE LLC | BusinessNameLine1Txt |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1001 CONSHOHOCKEN STATE ROAD STE 1- | AddressLine1Txt |
| City | WEST CONSHOHOCKEN | CityNm |
| State Abbreviation | PA | StateAbbreviationCd |
| ZIP | 19428 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 475492971 | EIN |
| Primary Activities | TO IMPROVE EFFICIENCIES IN PRECLINICAL RESEARCH. | PrimaryActivitiesTxt |
| Legal Domicile State | DE | LegalDomicileStateCd |
| Total Income | $1,459,166 | TotalIncomeAmt |
| End Of Year Assets | $3,020,407 | EndOfYearAssetsAmt |
Direct Controlling Entity Name DirectControllingEntityName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | TRANSCELERATE BIOPHARMA INC | BusinessNameLine1Txt |